secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0001193125-24-218828
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa prices upsized $225M ADS offering at $14.75/ADS; net proceeds ~$211M
-----------------------------------------------------------------------------

- Upsized offering: 15,254,237 ADSs at $14.75/ADS, gross proceeds ~$225M.
- Underwriters have 30-day option for additional 2,288,135 ADSs.
- Net proceeds ~$211M (or ~$242.7M with full overallotment) to fund product development and corporate.
- Company expects existing cash plus net proceeds to fund operations into mid-2027.
- Offering expected to close Sept 16, 2024; Goldman Sachs and Leerink Partners lead underwriters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312524218828/0001193125-24-218828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312524218828/d878816d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-218828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer